2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
Achiko AG
/ Key word(s): Miscellaneous
Achiko AG Announces Corporate Update Webcast Commercial Delivery of its Saliva-Based Covid-19 Test AptameXTM Has Commenced Zurich, 16 November 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) a healthcare technology company that is developing new innovations and disruptive diagnostic solutions that put people first announced today that it will hold a corporate update webcast for all shareholders and investors on Tuesday, November 22, 2022 at 3.00pm CET/9.00am EST. A PowerPoint presentation will be available at the time of the call and published on the company website at https://www.achiko.com/financials. Details of the webcast are as follows:
Find your local number: https://us02web.zoom.us/u/knHHcenwR Recently, Achiko announced that it is commencing commercial deliveries of its Generation 2 AptameX™ Covid-19 test kit to Nahdlatul Ulama and other commercial clients, both starting in and around Jakarta. Nahdlatul Ulama is the Jakarta branch of Nahdlatul Ulama, which nationally in Indonesia has over 90 million registered members and operates over 6,000 schools and universities, and several hundred hospitals and clinics. AptameX is the Company’s proprietary saliva-based Covid-19 test utilising DNA aptamers bound to gold nanoparticles in a colloidal solution. The result is read by a UV Spectrophotometer and then analysed with custom software. Unlike a molecular and immunoassay approaches, the test’s use of DNA aptamers has yielded encouraging results at low viral loads outperforming most lateral flow based rapid tests.
ABOUT ACHIKO AG Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport. AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022. The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field. Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.
Media contacts: ACHIKO AG Switzerland & Global
End of Media Release |
| Language: | English |
| Company: | Achiko AG |
| Tessinerplatz 7 | |
| 8002 Zurich | |
| Switzerland | |
| E-mail: | ir@achiko.com |
| Internet: | https://www.achiko.com/ |
| ISIN: | CH0522213468 |
| Valor: | 48788430 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1489695 |
| End of News | EQS News Service |
|
|
1489695 16.11.2022 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
